Distinct KRAS mutation subtypes reprogram the tumor microenvironment and shape survival outcomes in colorectal cancer
Yutong Liu, Yanjing Zhu, Shan Yu, Xiaojing Xu et autres
0 citationsJournal of Translational Medicine
Luoyan Ai
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
51Publications signalées
1584Citations signalées
6Affiliations récentes
Institutions déclarées
Domaines associés
Cancer Immunotherapy and BiomarkersAdvanced oxidation water treatmentColorectal Cancer Treatments and StudiesEnvironmental remediation with nanomaterialsPeroxisome Proliferator-Activated Receptors
Publications récentes
Targeting ATF3-mediated asparagine biosynthesis reverses acquired resistance to KRASG12C inhibitors
Yanjing Zhu, Chi Zhang, Min Li, Luoyan Ai et autres
0 citationsOncogene
Tislelizumab, bevacizumab, and chemotherapy as second-line therapy in PD-L1-positive, RAS-mutant metastatic colorectal cancer: A single-arm, phase II clinical trial.
0 citationsJournal of Clinical Oncology
NALIRIFOX plus targeted therapy as first-line treatment for metastatic colorectal cancer: A phase I study.
Xiaojing Xu, H Liu, Yanhong Gu, Peng Zhao et autres
0 citationsJournal of Clinical Oncology
Impact of synbindin deficiency on immune checkpoint blocker–induced systemic inflammation and multi-organ damage.
0 citationsJournal of Clinical Oncology
Tislelizumab plus cetuximab and irinotecan in relapsed/refractory RAS/BRAF wild-type and microsatellite stable metastatic colorectal cancer: A randomized, controlled, multicenter study (TEC2).
Xiaojing Xu, Y P Yu, T Liu, Minzhi Lv et autres
0 citationsJournal of Clinical Oncology
Rare earth-derived conductive zeolite electrodes empower NH4+ recovery from mining wastewater via FCDI and their application as ammonia release fertilizer
Wenrong Xiong, Yalan Zhang, Lijun Chen, Jiancheng Cheng et autres
1 citationWater Research
315P Identification of potential immune biomarkers associating to clinical benefit from intensive chemotherapy combined with serplulimab and trastuzumab in advanced HER2+ gastric cancer: A post-hoc analysis of the ASTRUM study
Luoyan Ai, T. Liu, Y. Wang, X. Xiao et autres
0 citationsAnnals of Oncology
Mechanistic insights into PD-1 inhibitor-associated immune thrombocytopenia: a case report integrating longitudinal transcriptomic profiling
Huishan Li, Yan Wang, Jianfeng Zhu, Hehui Chen et autres
3 citationsJournal for ImmunoTherapy of Cancer
Targeting WEE1 in ARID1A/TP53 Concurrent Mutant Colorectal Cancer by Exploiting R‐Loop Accumulation and DNA Repair Deficiencies
Yanjing Zhu, Luoyan Ai, Shan Yu, Yichen Wang et autres
3 citationsAdvanced Science
Safety, efficacy, and biomarker analysis from a phase II trial of intensive chemotherapy combined with serplulimab and trastuzumab in patients with advanced HER2-positive gastric cancer.
Tianshu Liu, Yan Wang, Xiuying Xiao, Luoyan Ai et autres
0 citationsJournal of Clinical Oncology
Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring
Heng Jiao, Siyun Lin, Jianmin Gu, Dongxian Jiang et autres
13 citationsMolecular Cancer
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.